Kuchikala Reddy, MD
Gastroenterology · Philadelphia, PANPI 1992848519
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $146,610 of the $181,815 with a category attached, or 80.6%. 16 manufacturers reported payments, led by Mallinckrodt Hospital Products Inc. at 53.8% of the total. Reporting peaked in 2024 at $66,462 and has fallen 87.2% since, to $8,502 in 2025. Among gastroenterology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 74 payments — averaging $2456.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$98K
- Pfizer$23K
- Spark Therapeutics, Inc.$16K
- Intercept Pharmaceuticals, Inc.$15K
- Daiichi Sankyo Inc.$8K
- Ipsen Biopharmaceuticals, Inc$5K
- plus $16K from 10 others
Across 328 payments — averaging $19,174 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mallinckrodt Hospital Products Inc.$4.4M
- Gilead$466K
- E.r. Squibb & Sons, L.L.C.$338K
- GSK$317K
- Bausch Health US, LLC$179K
- Grifols Therapeutics LLC$141K
- plus $449K from 9 others
What the payments were for
- Consulting fees$146,61081%
- Speaking & faculty fees$29,89216%
- Travel & lodging$3,5222%
- Food & beverage$1,7911%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 16 | $97,850 |
| Pfizer | 11 | $23,177 |
| Spark Therapeutics, Inc. | 4 | $15,872 |
| Intercept Pharmaceuticals, Inc. | 6 | $14,970 |
| Daiichi Sankyo Inc. | 8 | $8,403 |
| Ipsen Biopharmaceuticals, Inc | 2 | $5,112 |
| Mallinckrodt Enterprises LLC | 13 | $4,256 |
| Gilead | 5 | $3,676 |
| Sequana Medical US Inc. | 2 | $3,390 |
| AMAG Pharmaceuticals, Inc. | 1 | $2,800 |
| Theratechnologies Inc. | 1 | $2,000 |
| Medtronic | 1 | $167 |
| GSK | 1 | $59 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $57 |
| Merck | 1 | $17 |
| ERBE USA Inc | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$181,815 in reported general payments places this provider in the 95th percentile of 935 gastroenterology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ursodiol | 11 | $5,540 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Philadelphia
- Michael KochmanPhiladelphia$361K
- Gary LichtensteinPhiladelphia$342K
- Gregory GinsbergPhiladelphia$234K
- Neilanjan NandiPhiladelphia$209K
- David LichtensteinPhiladelphia$192K
- Alexander SchlachtermanPhiladelphia$188K
- James LewisPhiladelphia$175K
- Beth GardnerPhiladelphia$122K
- Gary FalkPhiladelphia$121K
- Adam EhrlichPhiladelphia$117K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.